Reducing clots in Scotland

January 2009
British Journal of Hospital Medicine (17508460);Jan2009, Vol. 70 Issue 1, p9
Academic Journal
The article offers information on the approval of Xarelto, rivaroxaban, by the Scottish Medicines Consortium for the prevention of venous thromboembolism in Scotland. The said drug was approved and accepted by the agency to be used in treating adult patients undergoing elective hip or knee replacement surgery within the National Health Service (NHS).


Related Articles

  • SMC accepts three drugs.  // PharmacoEconomics & Outcomes News;5/28/2011, Issue 629, p10 

    The article reports that the Scottish Medicines Consortium (SMC) approved Sunitinib, ticagrelor film-coated tablets and iron isomaltoside for use within the Scottish National Health Service (NHS).

  • SMC accepted 5 new drugs for use by NHS Scotland.  // PharmacoEconomics & Outcomes News;10/22/2016, Vol. 764 Issue 1, p36 

    The article reports on the approval given by the Scottish Medicines Consortium (SMC) on five new drugs for routine use of the National Health Service (NHS) Scotland, including aflibercept, budesonide and nivolumab.

  • NHS elections.  // Community Practitioner;Jan2009, Vol. 82 Issue 1, p5 

    The article reports on the plan of the Scottish Government to operate direct elections of National Health Service (NHS) health board in rural and urban area in Scotland. It highlights the statements of Unite/Community Practitioners' and Health Visitors' Association (Unite/CPHVA), where he...

  • Neonatal care in Scotland is 'at breaking point.'.  // Paediatric Nursing;Dec2007, Vol. 19 Issue 10, p5 

    The article reports on the findings of the study titled "Small Babies, Short Changed: Are We Ensuring the Best Start for Babies Born Too Soon in Scotland" that was released by premature baby charity Bliss. The report has revealed that the demand for nurses' time had increased five percent...

  • SMC approves six drugs.  // PharmacoEconomics & Outcomes News;3/19/2011, Issue 624, p10 

    The article enumerates the six medicines approved by the Scottish Medicines Consortium (SMC) for use within Scotland's National Health Service. It includes the botulinum toxin A Botox for patients with focal spasticity of the wrist and hand resulting from stroke and fosaprepitant dimeglumine or...

  • Positive SMC advice for six treatments.  // PharmacoEconomics & Outcomes News;Nov2013, Issue 691, p15 

    The article discusses the November 11, 2013 decision of the Scottish Medicines Consortium regarding the approval or rejection of several medicines for the National Health Service of Scotland. Topics mentioned include the approval of Atomoxetine as a treatment for attention deficit or...

  • Latest advice from the SMC.  // PharmacoEconomics & Outcomes News;1/7/2012, Issue 644, p10 

    The article announces the latest advice on a number of treatments issued by the Scottish Medicines Consortium (SMC) on December 12, 2011, including the approval of the use of apixaban for the prevention of venous thromboembolic events in adult patients who underwent hip or knee surgery.

  • Situation vacant. Ward, Seamus // Public Finance;05/02/97, p13 

    Looks at why the posts of finance directors for the Scottish National Health Service are hard to fill. Simon Featherstone's resignation; Featherstone's reason for leaving; Need for stability at the top; Possible impact of a Scottish Parliament with tax-raising powers.

  • U-turn on top finance post in Scottish NHS.  // Public Finance;11/4/94, p5 

    Reports on the search by the National Health Service in Scotland for a finance director. Placement of advertisements in newspapers; Reason for the urgency; Previous announcement of the calling off of the search.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics